[Autoimmune pancreatitis]

Area of Science:

• Gastroenterology and Immunology
• Pancreatic Diseases
• Autoimmune Disorders

Background:

• Autoimmune pancreatitis (AIP) is a benign fibroinflammatory pancreatic condition of likely autoimmune etiology.
• AIP presents with two distinct phenotypes: lymphoplasmacytic sclerosing pancreatitis (type 1) and idiopathic duct-centric pancreatitis (type 2).
• Its presentation often mimics pancreatic neoplasia, causing obstructive jaundice and leading to consideration for pancreaticoduodenectomy.

Purpose of the Study:

• To highlight the importance of considering autoimmune pancreatitis in the differential diagnosis of pancreatic masses and obstructive jaundice.
• To emphasize the diagnostic criteria and characteristic response to therapy for AIP.
• To inform clinicians about how recognizing AIP can alter patient management and prevent surgical intervention.

Main Methods:

• Review of historical and current diagnostic criteria for autoimmune pancreatitis, including the HISORT criteria and international consensus criteria (2011).
• Discussion of the clinical presentation, particularly obstructive jaundice and pancreatic mass.
• Emphasis on the therapeutic response to steroid treatment as a key diagnostic and management feature.

Main Results:

• Autoimmune pancreatitis can present clinically as a pancreatic mass with obstructive jaundice, necessitating its inclusion in the differential diagnosis.
• Established diagnostic criteria, such as HISORT and international consensus criteria, aid in identifying AIP.
• AIP demonstrates a remarkable and characteristic response to steroid therapy, distinguishing it from pancreatic cancer.

Conclusions:

• Accurate diagnosis of autoimmune pancreatitis is crucial for appropriate patient management.
• Recognition of AIP can prevent unnecessary pancreaticoduodenectomy in patients presenting with obstructive jaundice.
• Steroid therapy is the cornerstone of treatment for autoimmune pancreatitis, leading to favorable outcomes without surgery.